Antares Pharma: $ATRS A Risky Buy

Antares Pharmaceuticals is a Hot Biopharma Investment Right Now

 
So let's start off with Antares Pharma. Most of my previous stocks that I have written about have done very well in the past few years so I'll continue with that trend with this stock: ATRS.

ATRS FDA Approval PDUFA Date is Oct. 14th

     Antares Pharma

Here's a few web links to help you out on Antares and what they are all about. 

• From MarketWatch: ATRS Antares Pharma

• From Yahoo Finance:  Big News with Antares Pharma Welcomes Marvin Samson to Board of Directors, from Global Manufacturing Leader, TEVA

• From Morningstar, their analysis of Antares Stock ATRS

• Twitter Hashtag Search Data of $ATRS

• From Seeking Alpha:  4 Top Small Cap Biotech Acquisition Targets: Trius, Antares, Acadia, AcelRx Pharmaceuticals

• From Investor's Hub: ATRS

• From Sheff Station:  ATRS Biotech DD

• From Biotech Due Diligence: Antares ATRS Valuation 

This is what that blogger from Seeking Alpha, Scott Matusow has to say about Antares.  I agree with a commenter that a buyout would be a couple of years down the road.

Antares Pharma (ATRS)